The new partner will test oral yew alcohol

Athenex, Cancer Research UK's Portfolio Alliance and the NIHR Clinical Research Network Industry Alliance have announced a partnership to test chemotherapy drugs that can be oral in early clinical trials.The partnership will allow researchers to study Atsenex's innovative experimental drug Oraxol, the first oral preparation for the chemotherapy drug yew alcohol, in combination with other cancer treatments.Yew alcohol works by blocking the growth of cancer and is widely used in a range of cancer types, but can only be administered by dripping intravenously.The ability to take yew alcohol or so or so increases patients' chances of receiving treatment at home, rather than going to the hospital regularly, and may reduce the cost of medical care."Oraxol marks an important step forward in oral chemotherapy and could change the way most cancer patients receive chemotherapy," said Rudolf Kwan, Athenex's chief medical officer. , he continued, "By working with Cancer Research UK's Portfolio Alliance and the NIHR Clinical Research Network, our goal is to develop Oraxol in an unlikely way to bring new treatment options to more cancer patients." Clinicalmanaged by the partnership will be academically funded and supported and monitored by Cancer Research UK and the NIHR Clinical Research Network.Oraxol was recently awarded the title of PIM by the UK's Medicines and Healthcare Products Regulator (MHRA), which said it considered the drug a promising candidate for the UK's early drug programme, which was approved for use in Europe with the threat of the drug or severe debilitating symptoms that saved patients their lives.Athenex already has strong influence in North America and Asia; The new partnership with Atenex, Cancer Research UK and the NIHR Clinical Research Network Industry Alliance is part of a wider programme to enter Europe. (Compiled by this web)